Original Articles| Volume 46, ISSUE 12, P1698-1702, December 15, 1999

Reduction of the small synaptic vesicle protein synaptophysin but not the large dense core chromogranins in the left thalamus of subjects with schizophrenia

  • Mikael Landén
    Address reprint requests to Mikael Landén, Department of Psychiatry and Neurochemistry, Sahlgrenska University Hospital/Mölndal, S-431 80 Mölndal, Sweden
    Institute of Clinical Neuroscience, Department of Psychiatry and Neurochemistry, Göteborg University, Göteborg (ML, PD, C-GG, BG, KB), Sweden
    Search for articles by this author
  • Pia Davidsson
    Institute of Clinical Neuroscience, Department of Psychiatry and Neurochemistry, Göteborg University, Göteborg (ML, PD, C-GG, BG, KB), Sweden
    Search for articles by this author
  • Carl-Gerhard Gottfries
    Institute of Clinical Neuroscience, Department of Psychiatry and Neurochemistry, Göteborg University, Göteborg (ML, PD, C-GG, BG, KB), Sweden
    Search for articles by this author
  • Bengt GrenfeldtMats Stridsberg
    Institute of Clinical Neuroscience, Department of Psychiatry and Neurochemistry, Göteborg University, Göteborg (ML, PD, C-GG, BG, KB), Sweden

    Department of Clinical Chemistry, University Hospital, Uppsala (MS), Sweden
    Search for articles by this author
  • Kaj Blennow
    Institute of Clinical Neuroscience, Department of Psychiatry and Neurochemistry, Göteborg University, Göteborg (ML, PD, C-GG, BG, KB), Sweden

    The Medical Research Council, Stockholm (KB), Sweden
    Search for articles by this author


      Background: It has been hypothesized that a lesion in the neuronal circuits of thalamus might contribute to the symptoms in schizophrenia. It has also been suggested that impaired synaptic transmission is an important component of the pathophysiology of schizophrenia. In the present study we assess the synaptic integrity of thalamus by means of examining the protein levels of: (1) synaptophysin, a membrane bound protein of small synaptic vesicles, and (2) chromogranins, a family of soluble secretory proteins stored and released from the secretory large dense-core vesicles.
      Methods: The brains of 9 patients with schizophrenia and 9 age-matched control subjects were studied. The levels of synaptophysin and chromogranins were measured by radioimmunoassays.
      Results: The amount of synaptophysin in the left thalamus was significantly decreased (p = .036) in the schizophrenic group (2655 ± 605 nmol synaptophysin/mg total protein) compared to the control group (3248 ± 827 nmol synaptophysin/mg total protein). There were no differences between the groups in the levels of chromogranins, nor in the levels of synaptophysin of the right thalamus.
      Conclusions: These findings indicate defect synaptic function in the left thalamus of patients with schizophrenia. This may be the cause of a reduction of synaptic terminals or a defect limited to certain structures of the synapse, namely the small presynaptic vesicles.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Adolfsson R
        • Gottfries C.G
        • Nyström L
        • Winblad B
        Prevalence of dementia disorders in institutionalized Swedish old people. The work load imposed by caring for these patients.
        Acta Psychiatr Scand. 1981; 63: 225-244
      1. Alford MF, Masliah E, Hansen LA, Terry RD (1994): A simple dot-immunobinding assay for quantification of synaptophysin-like immunoreactivity in human brain. J Histochem Cytochem 42:283–237.

        • Anderson J
        • Fawdry R
        • Gordon E
        • Coyle S
        • Gruenewald S
        • Meares R.A
        SPECT asymmetry of left temporal lobe in hallucinating schizophrenics of the indifferentiated type.
        Biol Psychiatry. 1991; 29: 291S
        • Andreasen N.C
        Symptoms, signs, and diagnosis of schizophrenia.
        Lancet. 1995; 346: 477-481
        • Andreasen N.C
        The role of the thalamus in schizophrenia [see comments].
        Can J Psychiatry. 1997; 42: 27-33
        • Andreasen N.C
        • Arndt S
        • Swayze II, V
        • et al.
        Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging [see comments].
        Science. 1994; 266: 294-298
        • Barta P.E
        • Pearlson G.D
        • Powers R.E
        • Richards S.S
        • Tune L.E
        Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia.
        Am J Psychiatry. 1990; 147: 1457-1462
        • Benes F.M
        Neurobiological investigations in cingulate cortex of schizophrenic brain.
        Schizophr Bull. 1993; 19: 537-549
        • Blennow K
        • Davidsson P
        • Gottfries C.G
        • Ekman R
        • Heilig M
        Synaptic degeneration in thalamus in schizophrenia [letter].
        Lancet. 1996; 348: 692-693
        • Brown S
        Excess mortality of schizophrenia—A meta-analysis.
        Br J Psychiatry. 1997; 171: 502-508
        • Browning M.D
        • Dudek E.M
        • Rapier J.L
        • Leonard S
        • Freedman R
        Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics.
        Biol Psychiatry. 1993; 34: 529-535
        • Buchsbaum M.S
        • Someya T
        • Teng C.Y
        • et al.
        PET and MRI of the thalamus in never-medicated patients with schizophrenia.
        Am J Psychiatry. 1996; 153: 191-199
        • Cleghorn J.M
        • Garnett E.S
        • Nahmias C
        • et al.
        Regional brain metabolism during auditory hallucinations in chronic schizophrenia.
        Br J Psychiatry. 1990; 157: 562-570
        • DeLisi L.E
        • Buchsbaum M.S
        • Holcomb H.H
        • et al.
        Increased temporal lobe glucose use in chronic schizophrenic patients.
        Biol Psychiatry. 1989; 25: 835-851
        • Early T.S
        • Reiman E.M
        • Raichle M.E
        • Spitznagel E.L
        Left globus pallidus abnormality in never-medicated patients with schizophrenia.
        Proc Natl Acad Sci USA. 1987; 84: 561-563
        • Eastwood S.L
        • Burnet P.W
        • Harrison P.J
        Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia.
        Neuroscience. 1995; 66: 309-319
        • Eastwood S.L
        • Harrison P.J
        Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography.
        Neuroscience. 1995; 69: 339-343
        • Eastwood S.L
        • Heffernan J
        • Harrison P.J
        Chronic haloperidol treatment differentially affects the expression of synaptic and neuronal plasticity-associated genes.
        Mol Psychiatry. 1997; 2: 322-329
        • Fischer
        • Colbrie R
        • Hagn C
        • Schober M
        Chromogranins A, B, and C.
        Ann NY Acad Sci. 1987; 493: 120-134
        • Fischer von Mollard G
        • Mignery G.A
        • Baumert M
        • et al.
        rab3 is a small GTP-binding protein exclusively localized to synaptic vesicles.
        Proc Natl Acad Sci USA. 1990; 87: 1988-1992
        • Gabriel S.M
        • Haroutunian V
        • Powchik P
        • et al.
        Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia [published erratum appears in Arch Gen Psychiatry 1997 54:912].
        Arch Gen Psychiatry. 1997; 54: 559-566
        • Glantz L.A
        • Lewis D.A
        Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia.
        Arch Gen Psychiatry. 1997; 54: 943-952
        • Gur R.E
        Left hemisphere dysfunction and left hemisphere overactivation in schizophrenia.
        J Abnorm Psychol. 1978; 87: 226-238
        • Gur R.E
        • Resnick S.M
        • Gur R.C
        Laterality and frontality of cerebral blood flow and metabolism in schizophrenia.
        Psychiatry Res. 1989; 27: 325-334
        • Gur R.E
        • Resnick S.M
        • Gur R.C
        • et al.
        Regional brain function in schizophrenia. II. Repeated evaluation with positron emission tomography.
        Arch Gen Psychiatry. 1987; 44: 126-129
        • Hamos J.E
        • DeGennaro L.J
        • Drachman D.A
        Synaptic loss in Alzheimer’s disease and other dementias.
        Neurology. 1989; 39: 355-361
        • Jones E.G
        Cortical development and thalamic pathology in schizophrenia [see comments].
        Schizophr Bull. 1997; 23: 483-501
        • Kane J.M
        • McGlashan T.H
        Treatment of schizophrenia.
        Lancet. 1995; 346: 820-825
        • Karson C.N
        • Mrak R.E
        • Schluterman K.O
        • Sturner W.Q
        • Sheng J.G
        • Griffin W.S
        Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia.
        Mol Psychiatry. 1999; 4: 39-45
        • Knapp M
        Costs of schizophrenia.
        Br J Psych. 1997; 171: 509-518
        • Manaye K.F
        • German D.C
        • Liang C.L
        • Hicks P.B
        • Young K.A
        Reduced number of mediodorsal thalamic neurons in schizophrenia.
        Soc Neurosci Abstr. 1997; 23: 854.13
        • Masliah E
        • Terry R.D
        • Alford M
        • DeTeresa R
        Quantitative immunohistochemistry of synaptophysin in human neocortex.
        J Histochem Cytochem. 1990; 38: 837-844
        • Miller C.H
        • Mohr F
        • Umbricht D
        • Woerner M
        • Fleischhacker W.W
        • Lieberman J.A
        The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.
        J Clin Psychiatry. 1998; 59: 69-75
        • Munoz D.G
        • Kobylinski L
        • Henry D.D
        • George D.H
        Chromogranin A-like immunoreactivity in the human brain.
        Neuroscience. 1990; 34: 533-543
        • Pakkenberg B
        Stereological quantitation of human brains from normal and schizophrenic individuals.
        Acta Neurol Scand Suppl. 1992; 137: 20-33
        • Perrone Bizzozero N.I
        • Sower A.C
        • Bird E.D
        • Benowitz L.I
        • Ivins K.J
        • Neve R.L
        Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia.
        Proc Natl Acad Sci USA. 1996; 93: 14182-14187
        • Reynolds G.P
        Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia.
        Nature. 1983; 305: 527-529
        • Rossi A
        • Stratta P
        • D’Albenzio L
        • et al.
        Reduced temporal lobe areas in schizophrenia.
        Biol Psychiatry. 1990; 27: 61-68
        • Shenton M.E
        • Kikinis R
        • Jolesz F.A
        • et al.
        Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study.
        N Engl J Med. 1992; 327: 604-612
        • Somogyi P
        • Hodgson A.J
        • DePotter R.W
        • et al.
        Chromogranin immunoreactivity in the central nervous system. Immunochemical characterisation, distribution and relationship to catecholamine and enkephalin pathways.
        Brain Res. 1984; 320: 193-230
        • Stridsberg M
        • Hellman U
        • Wilander E
        • Lundqvist G
        • Hellsing K
        • Oberg K
        Fragments of chromogranin A are present in the urine of patients with carcinoid tumours.
        J Endocrinol. 1993; 139: 329-337
        • Stridsberg M
        • Lundqvist G
        • Engstrom U
        • et al.
        Development of polyclonal antibodies and evaluation of a sensitive radioimmunoassay for detection and measurement of synaptophysin.
        Acta Neuropathol. 1994; 87: 635-641
        • Stridsberg M
        • Oberg K
        • Li Q
        • Engstrom U
        • Lundqvist G
        Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.
        J Endocrinol. 1995; 144: 49-59
        • Wiedenmann B
        • Franke W.W
        Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles.
        Cell. 1985; 41: 1017-1028
        • Williamson P
        • Pelz D
        • Merskey H
        • Morrison S
        • Conlon P
        Correlation of negative symptoms in schizophrenia with frontal lobe parameters on magnetic resonance imaging.
        Br J Psychiatry. 1991; 159: 130-134